|
Description:
|
|
Contributor: Alec Coston, MD Educational Pearls: Disclaimer: this has nothing to do with the ER but is too cool to not talk about. -
Condition: Carbamoyl phosphate synthetase 1 (CPS1) deficiency -
Rare inborn error of metabolism -
Inability to properly break down ammonia -
Leads to severe hyperammonemia and hepatic encephalopathy -
Natural history: -
Without treatment, typically fatal within the first few weeks of life -
Even with current standard treatments, life expectancy is often limited to ~5–6 years -
Breakthrough treatment: -
A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the CRISPR-based targeted gene therapy for this patient. -
First-of-its-kind precision approach tailored to the patient's specific mutation -
Key components of the therapy: -
Whole-genome sequencing to identify the exact CPS1 mutation -
Creation of a custom base-editing enzyme designed to correct that specific mutation -
Design of a guide RNA to direct the base editor to the precise genomic location -
Delivery method: -
Why the liver works well: -
CPS1 is primarily expressed in hepatocytes -
The liver is relatively easy to target with lipid nanoparticles -
Hepatocytes divide frequently, allowing edited genes to be passed on as cells replicate -
Long-term impact: -
Once edited, cells continue producing functional CPS1 enzyme -
Potential for durable, possibly lifelong correction from a single treatment References -
https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment -
Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022 Feb 1;526:55-61. doi: 10.1016/j.cca.2021.11.029. Epub 2021 Dec 29. PMID: 34973183. -
Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026 Jan 5. doi: 10.1039/d5na00535c. Epub ahead of print. PMID: 41640466; PMCID: PMC12865601. Summarized and edited by Jeffrey Olson MS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf |